Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Pharma name with multiple recent catalysts: late May and June brought several U.S. approvals and positive late-stage updates including TRUQAP, BAXFENDY, IMFINZI, Datroway, IMFINZI/IMJUDO, and camizestrant SERENA-6 data; shares gained about 9.6% over 21 trading days.
Loading chart data...
Idea window: 7/2/2026 – 7/9/2026Sector: Healthcare
AI Analyst Overview
Loading AI Analyst data...
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 2 | Jul 9 | AZN | AstraZeneca PLC | Pharma name with multiple recent catalysts: late May and June brought several U.S. approvals and positive late-stage updates including TRUQAP, BAXFENDY, IMFINZI, Datroway, IMFINZI/IMJUDO, and camizestrant SERENA-6 data; shares gained about 9.6% over 21 trading days. | Closed | -8.5% |
| Feb 20 | Feb 27 | AZN | AstraZeneca PLC | Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188–195 range support near-term continuation for a disciplined momentum trade. | Closed | +2.1% |